Advectus Life Sciences Begins Preclinical Trials of P80DOX-NP

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 8
Volume 11
Issue 8

VANCOUVER, Canada-Ad-vectus Life Sciences Inc. has begun preclinical testing of its patented nanoparticle-based technology (Nanocure) at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure

VANCOUVER, Canada—Ad-vectus Life Sciences Inc. has begun preclinical testing of its patented nanoparticle-based technology (Nanocure) at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure formulation P80DOX-NP on rodent brain metastases arising from lung, breast, renal cell, and colon cancers, and melanoma, the company announced.

P80DOX-NP is a novel method for the delivery of doxorubicin across the blood-brain barrier. The randomized, placebo-controlled study will measure survival as a surrogate for intracranial tumor progression/regression.

Articles in this issue
Medicaid Gives New Protections to Beneficiaries in Managed Care Plans
Prostate Cancer Cell Line Vaccine Promising in Phase II Trial
MoAb Targeting Death Receptor in Breast Cancer
Hanford I-131 Releases Did Not Increase Thyroid Cancer Risk
Chemo/Rituximab Is Effective as First-Line CLL Therapy
Diagnostic Dilemma
Viral Agent ONYX-015 Targets p53-Deficient Cancer Cells
Program Educates Teens About Testicular Cancer Self-Exam
Better Colon Cancer Imaging With PET/CT Than With PET Alone
Delayed Lung Cancer Screening Trial to Begin Enrollment 50,000 Subjects
Results Similar With Weekly or Every-3-Week Irinotecan Dosing Regimens
Single-Dose Palonosetron Prevents Acute, Delayed Emesis
Adjuvant Chemo Controversy in Microsatellite Unstable Colon Cancer
Radiolabeled TNT MoAb Effective in Inoperable Lung Cancer
Multidetector CT Finds Peritoneal Ovarian Cancer Metastasis
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content
Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.

Zanidatamab Combo Has Meaningful Activity in HER2+ Gastroesophageal Cancer

Russ Conroy
July 5th 2025
Article

Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

As AI revolutionizes cancer care by enhancing diagnosis, treatment, and clinical trial matching, it may lead to improved patient outcomes and streamlined workflows.

Current Use and Future Directions of Artificial Intelligence in Hematology/Oncology

Julie M. Vose, MD, MBA
July 5th 2025
Article

As AI revolutionizes cancer care by enhancing diagnosis, treatment, and clinical trial matching, it may lead to improved patient outcomes and streamlined workflows.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC

Roman Fabbricatore
July 4th 2025
Article

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.

Diagnosing and Treating Patients With Epithelioid Sarcoma

ONCOLOGY Staff
July 4th 2025
Article

Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.